ADVANCED TRIPLE NEGATIVE BREAST CANCER
Clinical trials for ADVANCED TRIPLE NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED TRIPLE NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ADVANCED TRIPLE NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough breast cancer: experimental drug trial seeks to slow disease progression
Disease control Not yet recruitingThis study is testing whether the drug sacituzumab govitecan can slow cancer progression when used as the first treatment for advanced triple-negative breast cancer. Researchers will enroll 24 adults who haven't received prior treatment for their advanced cancer and give them the…
Matched conditions: ADVANCED TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Nathalie Levasseur • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New home care program aims to ease suffering for seriously ill patients
Symptom relief Not yet recruitingThis study is testing a new way to deliver palliative care at home for people with advanced heart failure or certain cancers. The program adjusts the level of support a patient receives based on how their symptoms and daily function change over time. It aims to improve quality of…
Matched conditions: ADVANCED TRIPLE NEGATIVE BREAST CANCER
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Apr 01, 2026 23:26 UTC
-
Common eye drop ingredient tested to stop cancer Drug's harsh side effect
Symptom relief Not yet recruitingThis study aims to see if giving atropine, a common medication, can prevent severe diarrhea in people with advanced breast cancer who are being treated with the drug sacituzumab govitecan. It will enroll about 30 adults with specific types of advanced breast cancer that has progr…
Matched conditions: ADVANCED TRIPLE NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: MedSIR • Aim: Symptom relief
Last updated Mar 30, 2026 14:29 UTC